Lion Biotechnologies to Present at the LD MICRO Conference on December 3
November 26 2013 - 8:00AM
Business Wire
Lion Biotechnologies, Inc. (OTC Markets: LBIO) announced that
Chief Financial Officer Michael Handelman will present at the 6th
Annual LD MICRO Conference on Tuesday, December 3, 2013, at 11:00
a.m. Pacific. The conference is being held at the Luxe Sunset Bel
Air Hotel in Los Angeles.
Mr. Handelman will be available for one-on-one meetings with the
investment community during the conference. Please contact LD Micro
organizers if you would like to arrange a meeting.
About Lion Biotechnologies
Lion Biotechnologies, Inc., formerly Genesis Biopharma, Inc., is
engaged in the development of T-cells and engineered T-cells for
the treatment of various cancers. The company's lead product
candidate is a ready-to-infuse autologous T-cell therapy utilizing
tumor-infiltrating lymphocytes (TILs) for the treatment of patients
with Stage IV metastatic melanoma, and is based on a clinical CRADA
with the National Cancer Institute along with physician-sponsored
investigational therapy at the MD Anderson Cancer Center and the H.
Lee Moffitt Cancer & Research Institute. For more information,
please visit http://www.genesis-biopharma.com/.
INVESTOR CONTACT:LHADon MarkleySenior Vice
President310-691-7100dmarkley@lhai.com